Approval · Notice of Compliance 20469 · 2018
CONTRAVE: Notice of Compliance 20469
Issued February 13, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20469
- Date
- February 13, 2018
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONTRAVE | 02472945 | Marketed |
Medicinal ingredients
- NALTREXONE HYDROCHLORIDE 8 MG per TAB
- BUPROPION HYDROCHLORIDE 90 MG per TAB